Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 332 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 4 mL injection of Placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337
View directory record Official record
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

NCT01932437
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Placebo
Biological · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 17, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

NCT05162027
View directory record Official record
Conditions
Temporomandibular Disorders
Interventions
Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 17, 2026, 7:36 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

NCT01783977
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 17, 2026, 7:36 AM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

NCT00725881
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Trans sodium crocetinate (TSC), 0.9% normal saline
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 17, 2026, 7:36 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

NCT01663402
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Alirocumab, Placebo, LMT
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
18,924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
273
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819
View directory record Official record
Conditions
HIV-1-infection
Interventions
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

NCT01194414
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Metoclopramide Versus Placebo for GJ Placement

NCT03331965
View directory record Official record
Conditions
Radiation Exposure, Enteral Nutrition
Interventions
Metoclopramide 5 MG/ML Injectable Solution, Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 17, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

NCT02367040
View directory record Official record
Conditions
Lymphoma,Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
16
States / cities
West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 17, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 17, 2026, 7:36 AM EDT